Patients should contact their GP, NHS 111, or healthcare provider if they experience any of the following: Severe or worsening itching that does not improve with simple measures or persists for more than 4872 hours Extensive redness, swelling, or warmth at the injection site, which may indicate cellulitis or another bacterial skin infection Development of a rash that spreads beyond the immediate injection site, particularly if accompanied by systemic symptoms Pain or tenderness that is disproportionate to the expected discomfort from a subcutaneous injection Discharge, pus, or bleeding from the injection site, suggesting possible infection or abscess formation Fever, chills, or malaise occurring in conjunction with injection site symptoms, which may indicate systemic infection or hypersensitivity Signs of a serious allergic reaction require immediate emergency attention
Many patients experience significant weight regain unless theyve implemented substantial lifestyle changes during treatment
The chronic average and titration peak describe different phases
Wegovy is FDA-approved for supporting weight loss in individuals who meet one of the following criteria: Have obesity, defined as a body mass index (BMI) of 30 kg/m or higher, or
If a clinic instruction lists a unit count that does not match a standard titration dose at your vial's concentration, stop
As tirzepatide was compared to controls, the hazard ratios for MACE-4 were 0.80 (95% confidence interval [CI], 0.571.11), cardiovascular death was 0.90 (95% CI, 0.501.61), and all-cause death was 0.80 (95% CI, 0.511.25) [2]
:format(webp))
